Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „analysis“
Suchtreffer
Begriffe & Kennungen
Capecitabine Teva · 4.8 · In addition to the ADRs described in tables 4 and 5, and based on the above pooled analysis from clinical safe
Eintrag öffnenCapecitabine Teva · 4.8 · The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabi
Eintrag öffnenCapecitabine Teva · 4.8 · The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabi
Eintrag öffnenCapecitabine Teva · 4.8 · The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabi
Eintrag öffnenChampix · 4.8 · 52 System Organ Adverse Drug Reactions Class Rare Semen analysis abnormal, C-reactive protein increased, blood
Eintrag öffnenChemometrik
Eintrag öffnenClusteranalyse
Eintrag öffnenComirnaty · 4.8 · 43 Adolescents 12 to 15 years of age – after 2 doses In an analysis of long-term safety follow-up in Study 2,
Eintrag öffnenComirnaty · 4.8 · Adolescents 12 to 15 years of age – after 2 doses In an analysis of long-term safety follow-up in Study 2, 2 2
Eintrag öffnenComirnaty · 4.8 · Adolescents 12 to 15 years of age – after 2 doses In an analysis of long-term safety follow-up in Study 2, 2 2
Eintrag öffnenComirnaty · 4.8 · Adolescents 12 to 15 years of age – after 2 doses In an analysis of long-term safety follow-up in Study 2, 2 2
Eintrag öffnenComirnaty · 4.8 · Adolescents 12 to 15 years of age – after 2 doses In an analysis of long-term safety follow-up in Study 2, 2 2
Eintrag öffnenComirnaty · 4.8 · At the time of the analysis of Study 2 with a data cut-off of 13 March 2021 for the placebo-controlled blinded
Eintrag öffnenComirnaty · 4.8 · At the time of the analysis of Study 2 with a data cut-off of 13 March 2021 for the placebo-controlled blinded
Eintrag öffnenComirnaty · 4.8 · At the time of the analysis of Study 2 with a data cut-off of 13 March 2021 for the placebo-controlled blinded
Eintrag öffnenComirnaty · 4.8 · At the time of the analysis of Study 2 with a data cut-off of 13 March 2021 for the placebo-controlled blinded
Eintrag öffnenComirnaty · 4.8 · At the time of the analysis of Study 2 with a data cut-off of 13 March 2021 for the placebo-controlled blinded
Eintrag öffnenComirnaty · 4.8 · Children 2 to 4 years of age – after 3 doses of the 3 mcg primary series In an analysis of Study 3 (Phase 2/3)
Eintrag öffnenComirnaty · 4.8 · Children 2 to 4 years of age – after 3 doses of the 3 mcg primary series In an analysis of Study 3 (Phase 2/3)
Eintrag öffnenComirnaty · 4.8 · Children 2 to 4 years of age – after 3 doses of the 3 mcg primary series In an analysis of Study 3 (Phase 2/3)
Eintrag öffnen